Entrada Therapeutics Inc Statistics
Want to see TRDA full AI Analyst Report?
Entrada Therapeutics Inc (TRDA) Stock Statistics & Valuation Metrics
Total Valuation
Entrada Therapeutics Inc has a market cap or net worth of $170.30M. The enterprise value is $123.37M.
- Market Cap
- $170.30M
- Enterprise Value
- $123.37M
Share Statistics
Entrada Therapeutics Inc has 39,150,333 shares outstanding. The number of shares has increased by 2.20% in one year.
- Shares Outstanding
- 39,150,333
- Owned by Insiders
- 54.35%
- Owned by Institutions
- 31.38%
Financial Efficiency
Entrada Therapeutics Inc’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.69%.
- Return on Equity (ROE)
- -0.47
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -43.69%
- Return on Capital Employed (ROCE)
- -0.44
- Revenue Per Employee
- 167.24K
- Profits Per Employee
- -945.72K
- Employee Count
- 152
- Asset Turnover
- 0.07
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Entrada Therapeutics Inc is -1.13. Entrada Therapeutics Inc’s PEG ratio is 0.02.
- PE Ratio
- -1.13
- PS Ratio
- 42.82
- PB Ratio
- 0.93
- Price to FCF
- -1.25
- Price to Operating Cash Flow
- -1.35
- PEG Ratio
- 0.02
Income Statement
In its last fiscal year, Entrada Therapeutics Inc had revenue of 25.42M and earned -143.75M in profits. Earnings per share was -3.47.
- Revenue
- 25.42M
- Gross Profit
- 21.32M
- Operating Income
- -156.00M
- Pretax Income
- -142.83M
- Net Income
- -143.75M
- EBITDA
- -138.73M
- Earnings Per Share (EPS)
- -3.47
Cash Flow
In the last 12 months, operating cash flow was -136.32M and capital expenditures -9,000, giving a free cash flow of -136.33M.
- Operating Cash Flow
- -136.32M
- Free Cash Flow
- -136.33M
- Free Cash Flow per Share
- -3.22
Dividends & Yields
Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―.
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -80.05%
- Earnings Yield
- -87.56%
Stock Price Statistics
- Beta
- 0.94
- 52-Week Price Change
- -52.56%
- 50-Day Moving Average
- 5.42
- 200-Day Moving Average
- 8.31
- Relative Strength Index (RSI)
- 40.55
- Average Volume (3m)
- 401.15K
Important Dates
Entrada Therapeutics Inc upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Entrada Therapeutics Inc has a current ratio of 12.53, with a Debt / Equity ratio of 16.64%.
- Current Ratio
- 12.53
- Quick Ratio
- 12.53
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.28
- Interest Coverage Ratio
- 0.00
Taxes
In its last fiscal year, Entrada Therapeutics Inc paid 924.00K in taxes.
- Income Tax
- 924.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Entrada Therapeutics Inc EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.77.
- EV to Sales
- 26.50
- EV to EBITDA
- -0.65
- EV to Free Cash Flow
- -0.77
- EV to Operating Cash Flow
- -0.77
Balance Sheet
Entrada Therapeutics Inc has $193.01M in cash and marketable securities with $47.31M in debt, giving a net cash position of $145.70M.
- Cash & Marketable Securities
- $193.01M
- Total Debt
- $47.31M
- Net Cash
- $145.70M
- Net Cash Per Share
- $3.72
- Tangible Book Value Per Share
- $4.68
Margins
Gross margin is 57.48%, with operating margin of -4303.82%, and net profit margin of -4057.98%.
- Gross Margin
- 57.48%
- Operating Margin
- -4303.82%
- Pretax Margin
- -4053.16%
- Net Profit Margin
- -4057.98%
- EBITDA Margin
- -4081.80%
- EBIT Margin
- -4053.16%
Analyst Forecast
The average price target for Entrada Therapeutics Inc is $17.75, which is 308.05% higher than the current price. The consensus rating is Strong Buy.
- Price Target
- $17.75
- Price Target Upside
- 308.05% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- -93.54%
- EPS Growth Forecast
- -53.55%
Scores
- Smart Score
- 6
- AI Score
- 45
